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Abstract
Background: This study was conducted to assess the impact of chikungunya on health costs during the epidemic that
occurred on La Re ´union in 2005–2006.
Methodology/Principal Findings: From data collected from health agencies, the additional costs incurred by chikungunya
in terms of consultations, drug consumption and absence from work were determined by a comparison with the expected
costs outside the epidemic period. The cost of hospitalization was estimated from data provided by the national
hospitalization database for short-term care by considering all hospital stays in which the ICD-10 code A92.0 appeared. A
cost-of-illness study was conducted from the perspective of the third-party payer. Direct medical costs per outpatient and
inpatient case were evaluated. The costs were estimated in Euros at 2006 values. Additional reimbursements for
consultations with general practitioners and drugs were estimated as J12.4 million (range: J7.7 million–J17.1 million) and
J5 million (J1.9 million–J8.1 million), respectively, while the cost of hospitalization for chikungunya was estimated to be
J8.5 million (J5.8 million–J8.7 million). Productivity costs were estimated as J17.4 million (J6 million–J28.9 million). The
medical cost of the chikungunya epidemic was estimated as J43.9 million, 60% due to direct medical costs and 40% to
indirect costs (J26.5 million and J17.4 million, respectively). The direct medical cost was assessed as J90 for each
outpatient and J2,000 for each inpatient.
Conclusions/Significance: The medical management of chikungunya during the epidemic on La Re ´union Island was
associated with an important economic burden. The estimated cost of the reported disease can be used to evaluate the
cost/efficacy and cost/benefit ratios for prevention and control programmes of emerging arboviruses.
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Introduction
Chikungunya virus infection is an arbovirus infection caused
by an Alphavirus of the family Togaviridae. This RNA virus is
transmitted to humans by mosquitoes of the genus Aedes, primarily
Aedes albopictus and Aedes aegypti.
Since 2005, the south-western Indian Ocean has seen the
emergence of large-scale epidemics of chikungunya, causing mil-
lions of cases in some countries [1–5]. In fact, 2005 and 2006 were
characterized by a particularly intense spread of the virus. The
chikungunya epidemic on La Re ´union involved about a third of the
population. During this outbreak, the surveillance system estimated
that 266,000 cases occurred [6–7]. This estimate was validated by a
seroprevalence survey conducted after the epidemic [8].
Chikungunya also affected other islands in the Indian Ocean:
Mayotte (involving about 38% of the population) [5–6], the Grande
Comoros (involving about 27% of the population) [9], Madagascar,
the Maldives [10], Mauritius [1,11] and the Seychelles [11]. In
India, more than 1.4 million cases were reported in 2006 [12].
Pakistan, Sri Lanka, Malaysia and Indonesia, where chikungunya is
endemic, were also affected [11]. Other regions of the world are
vulnerable to the spread of this virus or its vector [13], including
continental Europe. The risk of local transmission in these countries
isnotsimplytheoretical,asshownbytheepidemicofchikungunyain
the region of Emilia-Romagna, Italy, in2007 [14], and the detection
of two autochthonous cases in south-eastern France in 2010 [15].
The clinical presentation of the disease is characterized by
sudden onset fever, accompanied by disabling arthralgia and a
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myalgia, headache, digestive disorders and minimal haemor-
rhagic and cutaneous manifestations in the form of dyschromia
[4,16]. The signs of the disease generally fade after a few days,
but in some cases may persist for several months, particularly
regarding rheumatological manifestations [17–22]. Severe forms
were also described during the epidemic that raged on the island
of La Re ´union in 2005–2006, which in some cases were
associated with death [16,23–35]. A study conducted in the
general population at the end of the epidemic on La Re ´union
showed a seroprevalence of 38% [8]. Almost 85% of infections
were symptomatic [36].
The medical economic burden of chikungunya virus infection
was recently studied in India, and showed the major impact of this
disease on household finances in the absence of medical insurance
[37–39]. To the best of our knowledge, the economic impact of an
epidemic of chikungunya has never been measured in a country
with a high level of resources.
The French health care system is based on a universal ‘‘social
security’’ system funded by the government, employers and
the working population. For historical reasons, people are
insured against the risk of disease by schemes that are classi-
fied according to their profession: general scheme (most
employees, students, recipients of certain benefits and ordinary
residents), special scheme (certain categories of civil servants),
agricultural scheme (farmers and agricultural workers) and
autonomous scheme (artisans, merchants, industrials and liberal
professions).
The social security health insurance covers the cost of general
and specialized medicine consultations, drugs prescription,
laboratory analyses and hospitalization. In the case of sickness, it
also provides daily allowances to those who are insured and who
are unable to work. Private health insurances may be subscribed
to reimburse health related costs not covered by the social secu-
rity. For the most disadvantaged, State run programs provides
universal health coverage.
The objective of this study was to assess the medical costs of the
chikungunya epidemic on La Re ´union, a French overseas depar-
tment located in the Indian Ocean, during the period 2005–2006,
from a third payer perspective.
Methods
Estimation of outpatient medical costs
The direct medical costs of outpatients were defined as general
practice consultations, drugs prescription and chikungunya virus
specific serological tests. Data were provided by the social security
regional health insurance fund of La Re ´union and concerned the
general and agricultural schemes (75% of the island population).
The choice of drug classes used in this analysis was based on
data in the literature [3–4,40–42]. The treatments most frequently
reported for disease-related symptoms [3–4,40,42–44] essentially
involved analgesics and antipyretics. Since the use of non-steroidal
anti-inflammatory drugs has been regularly proposed for control-
ling the often severely painful manifestations of chikungunya
infection, reimbursement of the use of proton pump inhibitors
was also included in the analysis. Chloroquine and synthetic
antimalarials were incorporated because of their indications in the
management of certain forms of inflammatory rheumatism, but
also because of the initial presumption of their efficacy in the
management of the acute phase of chikungunya infection in the
context of the epidemic on La Re ´union [45]. Lastly, because of
the existence of neuropsychiatric manifestations reported in the
acute phase of this infection and subsequently [32,46], anxiolytics
were also included in this analysis.
The number of consultations and the drugs costs related to the
chikungunya epidemic were estimated from excesses observed
during the epidemic period.
Chikungunya serological tests were all attributed to the epi-
demic as these were not used before the outbreak of chikungunya
on the island.
In order to estimate the excess consultation and drug costs due
to the epidemic, we first determined what would have been
observed in the absence of an epidemic by using a periodic
regression model [47–48]. For this approach, the observed
number of consultations (or level of drugs costs) Yt at time t in
the absence of an epidemic is assumed to randomly fluctuate
around an expected value m(t). The expected value m(t) was
expressed as a periodic function account for seasonal effects, and
estimated by least squares fitting to Yt over the non-epidemic
period (defined as before March 1
st, 2005 and after June 30
th,
2006 [6,49]). This ‘‘expected’’ number in the absence of an epi-
demic, shown as a green curve in Figure 1 for analgesics
consumption, was estimated for each quantity (consultation,
antimalarials, proton pump inhibitors, anxiolytics). An upper
threshold, shown as the red curve in Figure 1, was computed as the
upper limit of the 95% prediction interval (m(t)+1.65 s, where s
was the residual standard deviation of the regression). Excess
periods, shown as blue areas in Figure 1, were define as periods
when the observations (number of consultations or drug costs)
were above this upper threshold (i.e. Y(t).m(t)+1.65 s). The
cumulated excess in consultations (or costs) were quantified by
cumulating differences between observed and expected (Yt – m(t))
during such excess periods. A lower bound for the excess was
calculated by cumulating differences only above the threshold (i.e.
Yt – m(t) – 1.65 s) instead of above the expected value, and an
upper bound was obtained by cumulating differences over the
whole epidemic period instead of over the excess period. These
values are reported as a range to illustrate uncertainty on the
estimates. To assess the reproducibility of the approach, an inde-
pendent estimate of analgesics consumption was obtained by
analysing the number of boxes sold by pharmacists (data IMS-
Health) during the period 2002 to 2008 (rather than reimburse-
ments from the social security).
Author Summary
For a long time, studies of chikungunya virus infection
have been neglected, but since its resurgence in the
south-western Indian Ocean and on La Re ´union Island, this
disease has been paid greater amounts of attention. The
economic and social impacts of chikungunya epidemics
are poorly documented, including in developed countries.
This study estimated the cost-of-illness associated with the
2005–2006 chikungunya epidemics on La Re ´union Island, a
French overseas department with an economy and health
care system of a developed country. ‘‘Cost-of-illness’’
studies measure the amount that would have been saved
in the absence of a disease. We found that the epidemic
incurred substantial medical expenses estimated at J43.9
million, of which 60% were attributable to direct medical
costs related, in particular, to expenditure on medical
consultations (47%), hospitalization (32%) and drugs
(19%). The costs related to care in ambulatory and
hospitalized cases were J90 and J2000 per case,
respectively. This study provides the basic inputs for
conducting cost-effectiveness and cost-benefit evaluations
of chikungunya prevention strategies.
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excess number of consultation times the mean social security rate
of one consultation (J26.4 in La Re ´union).
Estimation of hospitalization costs associated with the
chikungunya epidemic
The cost of the hospitalizations associated with chikungunya
was derived from the national database of hospital stays in
short-term care (PMSI database) [50]. All hospital stays between
March 1
st 2005 and June 30
th 2006 with ICD-10 code A92.0
(‘‘chikungunya fever’’) were included.
In France, the cost of hospitalization is determined on a
Diagnosis-Related Groups (DRG) basis [51–52]. The classification
of a patient in a given DRG is determined according to the final
diagnosis and management.
Here, the cost of a hospital stay was entirely attributed to chi-
kungunya when the code A92.0 appeared i) either as a principal
diagnosis (PD) or as a related diagnosis (RD) or ii) as an associated
diagnosis (AD) with a PD consistent with symptoms reported in the
acute phase of the disease (the codes concerned are reviewed in
Table 1) [4,16,53]. For hospital stays where chikungunya was coded
as an AD with a PD not consistent with a manifestation of the acute
stage of chikungunya, we only took into account the cost of days in
excess to the length of stay for this DRG, under the assumption that
chikungunya would lengthen the hospital stay (Figure 2). In order to
determine the lower estimate of the hospitalization costs related to
chikungunya, only stays with A92.0 coded as PD or RD were
considered; an upper limit was calculated by including all hospital
stays with a chikungunya code (PD, RD and AD, irrespective of the
length of stay for the latter). A previous study showed the absence of
long-termconsequencesonmedical consumption,sothat only acute
manifestations were considered [22].
Absenteeism costs
Data relating to absenteeism were also collected from the social
security regional fund of La Re ´union, including the number of
days of sick leave from work. The estimate of absenteeism costs
due to the chikungunya epidemic was determined from the excess
absence observed during the epidemic period according to the
method used to evaluate outpatient medical costs, as described
above. Thus, a periodic regression model was adjusted for the
number of days of absence from work outside the epidemic period
(between 2005 and 2008). We used the same method to evaluate
the excess number of people who had taken sick leave.
In order to evaluate absenteeism costs, the excess number of
days of absence from work was multiplied with the average
Figure 1. Excess reimbursement of analgesics during the Chikungunya epidemic on La Re ´union, 2005–2006. The black curve
represents the observed reimbursement costs in Euros, and the green curve the ‘‘expected’’ reimbursement cost in the absence of epidemic, derived
from the fit of a periodic regression model to observed costs outside the epidemic period. The red curve represents the upper limit of the 95%
prediction interval for monthly costs in the absence of epidemic. Excess periods are defined when the observed costs are above the threshold (area in
blue) and quantified by the cumulated difference between observed and expected costs over such periods.
doi:10.1371/journal.pntd.0001197.g001
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Institute for Statistics and Economic Studies), the median wage
(which corresponds to the sum of net wages earned by an
individual) amounted to J17,000 in 2006. By considering a
ratio of 1:2 between the net salary and gross salary, the annual
gross salary amounted to J34,000, which gave a gross daily
Table 1. ICD-10 codes of signs that may be related to Chikungunya virus infection.
ICD-10* chapters and groups of conditions concerned ICD-10 code concerned
Chapter I: Certain infectious and parasitic diseases
Intestinal infectious diseases A08, A09
Other bacterial diseases A40, A41, A46
Viral infections of the central nervous system A83, A86
Arthropod-borne viral fevers and viral haemorrhagic fevers A94
Viral infections characterized by skin and mucous membrane lesions B09
Viral hepatitis B17, B19
Other viral diseases B34
Chapter III: Diseases of the blood and blood-forming organs and certain disorders involving
the immune mechanism
Coagulation defects, purpura and other haemorrhagic conditions D69
Other diseases of blood and blood-forming organs D72, D762
Chapter IV: Endocrine, nutritional and metabolic diseases
Metabolic disorders E86
Chapter V: Mental and behavioural disorders
Mood disorders F32
Chapter VI: Diseases of the nervous system
Inflammatory diseases of the central nervous system G04, G05
Episodic and paroxysmal disorders G40.9, G43.9
Diseases of myoneural junction and muscle G72.4
Other disorders of the nervous system G93.3
Chapter XII: Diseases of the skin and subcutaneous tissue
Infections of the skin and subcutaneous tissue L08
Bullous disorders L13, L14
Dermatitis and eczema L29, L30
Urticaria and erythema L54.8
Chapter XIII: Diseases of the musculoskeletal system and connective tissue
Arthropathies M01.8, M06, M13, M25
Soft tissue disorders M65.8, M63.8, M79
Chapter XV: Pregnancy, childbirth and the puerperium
Other obstetric conditions, not elsewhere classified O98.5, O99.8
Chapter XVI: Certain conditions originating in the perinatal period
Foetus or newborn affected by maternal factors and by complications of pregnancy, labour and delivery P00.2
Disorders related to length of gestation and foetal growth P05**, P07**
Chapter XVII: Congenital malformations, deformations and chromosomal abnormalities
Other congenital malformations Q81.9
Chapter XVIII: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Symptoms and signs involving the digestive system and abdomen R11
Symptoms and signs involving the skin and subcutaneous tissue R21
Symptoms and signs involving the nervous and musculoskeletal systems R29.8
General symptoms and signs R50, R51, R52, R53, R55**, R56.0
Chapter XXI: Factors influencing health status and contact with health services
Persons encountering health services in circumstances related to reproduction Z35.8**, Z38.0**
*The International Statistical Classification of Diseases and Related Health Problems 10th Revision.
**Where the code A92.0 was the only AD.
This list of manifestations was compiled following a review of all of the ICD-10 codes by two of the authors (MKS and TH), based on the symptoms reported in the acute
phase of the disease. [4,16,53].
doi:10.1371/journal.pntd.0001197.t001
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average.
Cost analysis
In order to evaluate the medical costs related to the epidemic,
we performed a cost-of-illness study from the third-party payer
perspective. Intangible costs (non-financial costs such as the impact
of the disease on quality of life) and non-medical direct costs
(transport, home help) were not included in this analysis. Similarly,
costs borne by the patient or their private insurance companies
were not included.
This estimation established the total direct medical costs
(consultations, serological tests, drug consumption and hospital-
ization) and indirect medical costs (such as disease-related loss of
productivity) resulting from all cases of chikungunya during the
epidemic on La Re ´union.
The direct medical costs were reported for each outpatient case
and for each inpatient case. For the outpatients, the database
provided by the social security regional fund of La Re ´union was
that of the general and agricultural schemes which covers 75% of
the population of the island (source: social security fund of La
Re ´union). Therefore, we undertook the analysis by assuming that
the data were only related to 75% of the cases of chikungunya
(i.e. 199,500 people). For the inpatients, the database included all
of the hospitalized cases of chikungunya that had been used to
calculate the cost per inpatient.
All of the costs were rounded off to the nearest hundred
thousand Euros for the total population and the nearest unit for
the cost per case.
All data were analysed using periodic regression software [54]
and Stata10.0
TM software (StataCorp 2008, Texas, USA). The
costs were estimated in Euros at 2006 values.
Results
The additional number of consultations during the epidemic
compared to non-epidemic periods was 470,000 (range=195,000–
765,000), an increase of 25% (range=16–35%), corresponding to
an average of 2 additional consultations per case. The cost of these
additional consultations amounted to J12.4 million (Tables 2 and
3).
The excess cost for drugs was 59% (54–64%) for antimalarials,
44% (16–71%) for analgesics, 30% (9–50%) for proton pump
inhibitors and 24% (0–52%) for anxiolytics, yielding a total excess
cost of J5.0 million (Tables 2 and 3).
Analysis of drug pharmacy sales data also showed an increase of
35% (0–82%) for pain relievers (Figure 3).
The amount of expenditure occasioned by the serological tests
was J570,000 for a total number of 29,664 procedures.
The code A920 appeared as the principal, related or associated
diagnosis in 6175 hospital stays between March 2005 and June
2006. The inpatient population consisted of 40% men and the
mean age was 49629 years (range: 0–101 years). The code A92.0
appeared as a PD, RD or AD for 2771 (45%), 30 (0.5%) and 3374
(50.5%) patients, respectively. Among the patients for whom this
code appeared as an AD, 1248 (i.e. 37%) had a PD for which the
ICD-10 code was that of a symptom related to the infection. Based
on the algorithm defined in Figure 2, the number of stays included
in the estimate of expenses associated with hospitalizations for
Figure 2. Algorithm for the scale of charges for hospital stays associated with Chikungunya.
doi:10.1371/journal.pntd.0001197.g002
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567 days (range: 0–146 days) with a median of 3 days, giving a
total of 22,134 days. The cost distribution of hospitalization was
skewed towards larger values, with a range of J215 to J8000 and,
a median at J1600 and, a mean at J2000 per hospitalization. The
total cost for all hospitalizations for chikungunya was J8.5 million
(J5.8 million–J8.7 million) (Table 3).
Compared with non-epidemic periods, the chikungunya
epidemic led to an additional 112,400 (range=62,400–112,400)
days of absence from work for 12,800 (range=10,700–13,600)
subjects, the cost of which was estimated at J17.4 million
(Table 3).
The direct and indirect medical costs totalled J43.9 million
(Table 3).
Applying this expenditure to subjects affiliated with the general
and agricultural social security schemes in La Re ´union (i.e. 75% of
cases, n=199,500) only, the cost of outpatient care was estimated
as J90 per case for direct costs and J177 per case for all direct
and indirect costs.
The mean cost per inpatient case was J20006J1800 and the
mean cost per subject with sick leave was J1360.
Discussion
This study estimated the medical costs associated with the
chikungunya epidemic that occurred in 2005–2006 on La
Re ´union Island, a French overseas department with the economy
and health care system of a developed country. The epidemic
incurred substantial medical expenses for the third-party health
care payer, estimated as J43.9 million, of which 60% was
attributable to direct medical costs related, in particular, to
expenditure on medical consultations (47%), hospitalization (32%)
and drug consumption (19%).
‘‘Cost-of-illness’’ types of analysis are interested in the amount
that would have been saved in the absence of a disease and
which could have been allocated to other sectors. For example,
the chikungunya epidemic on La Re ´union occasioned greater
expenses for the National Health Insurance than occurred for
the reimbursement of anti-flu vaccines for the whole of France,
estimated in 2006 as being more than J19 million [55].
‘‘Cost-of-illness’’ studies can help in public health decisions and
in the prioritization of health care expenditure by third-party
payers. Although they do not take into account the benefits that
may be derived from the expenditure they estimate, they are a
useful and essential preliminary analysis before cost-efficacy or
cost-benefit analyses are undertaken.
To the best of our knowledge, the only published data on an
economic evaluation of an epidemic of chikungunya came from
surveys conducted in India [38–39]. However, the differences in
terms of the economic profile and health system organization
between La Re ´union and India limit the value of a direct com-
parison of the cost per case. Moreover, it should be noted that
epidemiological situations in Asian countries are characterized by
recurrent outbreaks with an endemic background, which are very
different from those in the Indian Ocean islands where the first
Table 3. Medical costs related to the Chikungunya epidemic, La Re ´union, 2005–2006.
Costs Parameters Total cost (in millions of Euros) Proportion of total cost
Direct costs 26.5 60%
Consultations 12.4 47%
Drugs 5 19%
Serological tests 0.57 2%
Hospitalizations 8.5 32%
Indirect costs 17.4 40%
Sick leave 17.4 100%
Total medical cost 43.9 100%
doi:10.1371/journal.pntd.0001197.t003
Table 2. Consultations, drug reimbursements and absenteeism from work due to the Chikungunya epidemic, La Re ´union, 2005–
2006.
Parameter Proportion of excess* [range] Quantification of excesses (in thousands) [range]
Consultations (services) 25% [16–35%] 470 [195–765]
Drugs reimbursements (cost in Euros)
Antimalarials 59% [54–64%] 36.2 [12.7–61.1]
Analgesics 44% [16–71%] 4027 [2467.1–4720.2]
Proton pump inhibitors 30% [9–50%] 876.5 [432.9–1187.2]
Anxiolytics 24% [0–52%] 43.4 [15–78.5]
Sick leave
Number of people concerned 137% [0–275%] 12.8 [10.7–13.6]
Number of days reimbursed 53% [15–92%] 112.4 [62.4–112.4]
*Compared to consumption outside the epidemic, calculated by a periodic regression model.
doi:10.1371/journal.pntd.0001197.t002
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populations. On the other hand, economic evaluations in eco-
nomically developed countries have been conducted following
epidemics of arboviruses other than chikungunya. This is the case
with the Ross River Virus (RRV) epidemic that occurred in
Australia in the 1990s. This arbovirus, also caused by an Alpha-
virus, has a very similar clinical presentation to that observed in
chikungunya virus infection. From the data supplied by Harley et
al. and Mylonas et al. [56–57], it is possible to estimate that the
direct medical costs for outpatient care resulting from the RVV
infection were between J61 and J121 per case (figures updated
for the year 2006), which are of the same order as those reported
in our study for chikungunya. Cost-of-illness studies have also
been conducted on other arboviruses such as dengue. For exam-
ple, a cost-of-illness study was conducted in Cambodia, a country
with poor health and economic indicators, in order to determine
the cost of dengue. During the 2007 dengue epidemic, the direct
medical cost per case was US$29, in which out-of-pocket repre-
sented 60% [58]. By reporting the outpatient costs (J90) and
inpatient costs (J2000) due to chikungunya as a percentage of the
GDP (Gross Domestic Product) per capita of La Re ´union
(J16,260/inhabitant in 2006), our estimations were found to be
considerably higher (0.6% and 12.3% of the GDP, respectively)
than those reported by Beauty et al. (0.03% and 0.17% of the GDP
respectively) in Cambodia [58]. The cost of dengue cases was
also estimated in eight countries in the Americas and Asia in a
prospective study [59]. The direct medical costs were I$116
for outpatients and I$915 for inpatients (expressed in international
Dollars (I$) at 2005 value). However, a comparison with chi-
kungunya is difficult because, on the one hand, dengue can be a
much more serious disease and, on the other hand, the health
systems and economic contexts in these countries are different
from those of France, where the largest share of health expen-
diture is devoted to public insurance.
During the epidemic period, only a proportion of all of the
drug prescriptions was attributable to chikungunya. Using the
periodic regression model we were able to determine this con-
tribution to the costs of consultations and drugs, as well as to the
daily payments to those on sick leave. Regarding the item relating
to the serological tests, these were performed so infrequently on La
Re ´union before the chikungunya epidemic that all the reimburse-
ments made during the epidemic period were taken into account
in the costing.
The excess costs of chikungunya were estimated by subtracting
the expected costs in the absence of an epidemic from observed
costs. The expected costs were extrapolated from available data
outside the epidemic period, under the hypothesis that such costs
would be stationary, albeit seasonally varying, from one year to the
next. Available data to estimate the expected costs included the
beginning of 2005 and years 2007–2008 or, in other words, essen-
tially post-epidemic periods. Visual inspection of the monthly time
series did not evoke a marked before/after epidemic change in
Figure 3. Excess sales of analgesics observed during the Chikungunya epidemic on La Re ´union, 2005–2006. The black curve represents
the observed number of boxes sold, and the green curve the expected number of boxes sold. The red curve represents the upper limit of the 95%
prediction interval. Excesses are represented by the areas painted in blue (source of the data: IMS Health).
doi:10.1371/journal.pntd.0001197.g003
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this way. Concerning the variability of the estimates, our approach
was primarily pragmatic, as the main source of uncertainty was
how to define excesses rather than statistical variability. The
ranges reported are therefore not confidence intervals in the
statistical sense, yet illustrate the likely range of excess costs. Since
the cost of analgesics accounted for 80% of the drug expenditure
related to chikungunya, we checked for a possible bias by ana-
lysing the data for drug sales in pharmacies from 2002 to 2008 and
found an increase of 35% in the sales of boxes of analgesics during
the epidemic period, a proportion similar to that for the increased
reimbursement of analgesics found in this study (44%). These data,
which are presented in Figure 3, confirm the results of our analysis
based on the data of the social security regional health insurance
fund of La Re ´union.
Our study had some limitations. First, the evaluation of health
care expenses did not take into account consultations with spe-
cialists (rheumatologists or dermatologists, for example). However,
on La Re ´union Island, the number of specialists is very small and
general practitioners retain a predominant role. Second, the cost
of manifestations in the late phase of the disease were not included
in our analysis, but we have previously shown that these mani-
festations did not lead to a significant increase in drug con-
sumption [22]. Third, the estimate of indirect costs reported here
did not take into account the fact that social security does not
cover an absence from work for fewer than 3 days, which
represents a possible source of cost underestimation. Fourth,
indirect costs in cost-of-illness analyses often evaluate productivity
losses, including costs from the perspective of the patients (and
often the caregivers), which was not the case in the present study.
As our study was not patient based, it was not possible to assess the
costs from the patient’s point of view.
The costs of this disease were estimated from the third-party
payer’s perspective. If the perspective were to be widened, this
would increase the estimate of the cost of the disease by including,
for example, direct medical costs not reimbursed by social security
(self-medication, alternative medicines, the proportion of costs
borne by the patient or his/her medical insurance company) and
non-medical direct costs (transport costs, childcare costs) and
intangible costs (loss of well-being, pain, immobilization).
Fifth, self-medication was certainly part of the spending, but we
were not able to find specific data about this. In France, the self-
medication market is less well developed than in neighbouring
countries (such as Poland, England, Italy, Germany). Indeed, these
drugs only represented 6% and 6.5% of all drugs sold in 2006 and
in 2009, respectively [60].
On La Re ´union, alternative medicines are generally based on
the use of products (zerbages or herbal tea infusions) that have not
had their therapeutic efficacy demonstrated (Noni juice, tonics,
essential oils) and which are not covered by the National Health
Insurance scheme, even though the burden falls on households.
These are costs that are difficult to measure retrospectively. Sixth,
concerning private insurance, we could not obtain precise infor-
mation on its coverage in La Re ´union. However, social security
reimburses a large share of the costs; for the most disadvantaged,
the costs are reimbursed in full.
The high cost of management explains the high expenditure
involved in combating disease. In fact, the amount of economic
assistance provided by the French state for the health crisis of
chikungunya, as notified by the general secretariat for regional
affairs (SGAR) in La Re ´union, was higher than the budget set
aside for the direct medical costs of the epidemic. Thus, J31.5
million was spent under the Intervention Fund for the Support of
Crafts and Trade (FISAC) and the Exceptional Aid Fund (FSE)
(source: Prefecture of La Re ´union). The increased activity resulting
from the epidemic also incurred costs in hospitals. By 31
st March
2006, J11.9 million had been allocated by the La Re ´union
Regional Hospitalization Agency to cover the costs associated with
the additional expenditure on personnel, insect control, hospital
equipment and research.
Cost estimates of a disease may be used to evaluate the cost/
benefit ratio of monitoring, prevention and control programmes of
arboviruses such as chikungunya, whether in the context of La
Re ´union (where re-emergence remains a possibility) or in other
regions of the world (that are vulnerable to the spread of this virus
or its vector). Cost estimates will also be essential in evaluating the
efficacy of candidate vaccines or future vaccination strategies.
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